Mendlein John
Director at FATE
- Sold, on record
- $1.1M
- Dollars the filings state
- Form 4 sales
- 2
- Latest Jun 3, 2022
- Form 144 notices
- 1
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 1
- Filed as an executive or holder
Companies
- FATEFATE THERAPEUTICS INCDirector
Sales by reason
0
Routine
2
Plan not stated
0
No plan
0
Unusual
Form 4 sales per year, every sale on record.
Timeline
- Dec 29, 2025Notice
Filed a notice to sell 38,428 shares
$39k38,428 shares
- Jun 3, 2022Plan not stated
Sold 0.9% of their holdings
$31k1,364 shares at $22.79
- Mar 10, 2022Plan not stated
Sold 16.5% of their holdings
$1.1M31,562 shares at $35.02
3 of 3
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2025 | May 30, 2025 | FATE | Director | AwardedStock Option (Right to Buy) | 55,000 | 55,000 | SEC | ||
| Jun 20, 2024 | Jun 21, 2024 | OMGA | Director | AwardedStock Option (Right to Buy) | 25,000 | 25,000 | SEC | ||
| Jun 7, 2024 | Jun 11, 2024 | FATE | Director | AwardedStock Option (Right to Buy) | 40,000 | 40,000 | SEC | ||
| Jun 7, 2023 | Jun 9, 2023 | OMGA | Director | AwardedStock Option (Right to Buy) | 18,118 | 18,118 | SEC | ||
| Jun 6, 2023 | Jun 7, 2023 | FATE | Director | AwardedStock Option (Right to Buy) | 40,000 | 40,000 | SEC | ||
| Jan 19, 2023 | Jan 20, 2023 | FATE | Director | Exercised or settledStock Option (Right to Buy) | 28,461 | 0 | SEC | ||
| Jan 19, 2023 | Jan 20, 2023 | FATE | Director | Exercised options | 28,461 | $1.37 | $39k | 311,231 | SEC |
| Jan 13, 2023 | Jan 13, 2023 | FATE | Director | Bought | 124,679 | $5.60 | $698k | 282,770 | SEC |
| Jun 9, 2022 | Jun 13, 2022 | FATE | Director | AwardedStock Option (Right to Buy) | 11,893 | 11,893 | SEC | ||
| Jun 9, 2022 | Jun 13, 2022 | FATE | Director | Awarded | 8,650 | 166,741 | SEC | ||
| Jun 8, 2022 | Jun 10, 2022 | OMGA | Director | AwardedOption (Right to Buy) | 18,118 | 18,118 | SEC | ||
| Jun 3, 2022 | Jun 6, 2022 | FATE | Director | Sold | 1,364 | $22.79 | $31k | 158,091 | SEC |
| Mar 10, 2022 | Mar 11, 2022 | FATE | Director | Sold | 31,562 | $35.02 | $1.1M | 159,455 | SEC |
| Mar 10, 2022 | Mar 11, 2022 | FATE | Director | Exercised or settledStock Option (Right to Buy) | 31,562 | 0 | SEC | ||
| Mar 10, 2022 | Mar 11, 2022 | FATE | Director | Exercised options | 31,562 | $1.63 | $51k | 191,017 | SEC |
| Jun 2, 2021 | Jun 4, 2021 | FATE | Director | AwardedStock Option (Right to Buy) | 4,334 | 4,334 | SEC | ||
| Jun 2, 2021 | Jun 4, 2021 | FATE | Director | Awarded | 2,681 | 159,455 | SEC | ||
| May 1, 2020 | May 5, 2020 | FATE | Director | AwardedStock Option (right to buy) | 16,000 | 16,000 | SEC | ||
| May 8, 2019 | May 10, 2019 | ATYR | Director | AwardedStock Option (right to buy) | 20,000 | 20,000 | SEC | ||
| May 3, 2019 | May 7, 2019 | FATE | Director | AwardedStock Option (right to buy) | 16,000 | 16,000 | SEC | ||
| Dec 21, 2018 | Dec 26, 2018 | ATYR | Director | Bought | 245,000 | $0.42 | $102k | 615,382 | SEC |
| May 15, 2018 | May 17, 2018 | ATYR | Director | AwardedStock Option (right to buy) | 20,000 | 20,000 | SEC | ||
| May 2, 2018 | May 4, 2018 | FATE | Director | AwardedStock Option (right to buy) | 16,000 | 16,000 | SEC | ||
| Jan 2, 2018 | Jan 2, 2018 | ATYR | Director | AwardedStock Option (right to buy) | 32,000 | 32,000 | SEC | ||
| Aug 31, 2017 | Sep 5, 2017 | ATYR | CEO and Director | BoughtWarrant to Purchase Common Stock | 14,151 | 14,151 | SEC | ||
| Aug 31, 2017 | Sep 5, 2017 | ATYR | CEO and Director | Bought | 37,736 | $2.65 | $100k | 367,883 | SEC |
| Jun 15, 2017 | Jun 19, 2017 | EDIT | Director | AwardedStock Option (right to buy) | 11,538 | 11,538 | SEC | ||
| May 2, 2017 | May 4, 2017 | FATE | Director | AwardedStock Option (right to buy) | 25,000 | 25,000 | SEC | ||
| Apr 24, 2017 | Apr 26, 2017 | ATYR | CEO and Director | Bought | 124 | $3.00 | $372 | 327,647 | SEC |
| Apr 20, 2017 | Apr 20, 2017 | ATYR | CEO and Director | Bought | 2,552 | $3.00 | $8k | 327,523 | SEC |
| Feb 7, 2017 | Feb 9, 2017 | ATYR | CEO and Director | AwardedEmployee Stock Option (right to buy) | 185,000 | 185,000 | SEC | ||
| Dec 19, 2016 | Dec 21, 2016 | ATYR | CEO and Director | Bought | 69,000 | $2.20 | $152k | 324,971 | SEC |
| May 11, 2016 | May 13, 2016 | FATE | Director | AwardedStock Option (right to buy) | 25,000 | 25,000 | SEC | ||
| Apr 5, 2016 | Apr 7, 2016 | ATYR | CEO and Director | Bought | 2,500 | $3.52 | $9k | 250,971 | SEC |
| Apr 5, 2016 | Apr 6, 2016 | ATYR | CEO and Director | Bought | 2,500 | $3.55 | $9k | 248,471 | SEC |
| Feb 3, 2016 | Feb 4, 2016 | EDIT | Director | AwardedStock Option (right to buy) | 96,153 | 96,153 | SEC | ||
| Jan 27, 2016 | Jan 29, 2016 | ATYR | CEO and Director | AwardedEmployee Stock Option (right to buy) | 135,000 | 135,000 | SEC | ||
| Jan 4, 2016 | Jan 6, 2016 | ATYR | CEO and Director | AwardedEmployee Stock Option (right to buy) | 148,732 | 148,732 | SEC | ||
| Oct 1, 2015 | Oct 5, 2015 | ATYR | Officer, Director | AwardedEmployee Stock Option (right to buy) | 136,070 | 65,070 | SEC | ||
| May 13, 2015 | May 15, 2015 | FATE | Director | AwardedStock Option (right to buy | 10,000 | 10,000 | SEC | ||
| May 12, 2015 | May 14, 2015 | ATYR | CEO and Executive Chairman | ConvertedSeries C Redeemable Convertible Preferred Stock | 191,340 | 0 | SEC | ||
| May 12, 2015 | May 14, 2015 | ATYR | CEO and Executive Chairman | Converted | 24,055 | 245,971 | SEC | ||
| May 6, 2015 | May 8, 2015 | ATYR | CEO & Executive Chariman | AwardedStock Option (right to buy) | 163,437 | 163,437 | SEC | ||
| Jun 6, 2014 | Jun 9, 2014 | FATE | Director | AwardedStock Option (right to buy) | 10,000 | 10,000 | SEC | ||
| Oct 4, 2013 | Oct 7, 2013 | FATE | Director | Bought | 16,667 | $6.00 | $100k | 156,774 | SEC |
| Jan 16, 2009 | Jan 21, 2009 | Monogram Biosciences, Inc. | Director | AwardedStock Option (Rt to Buy) | 3,500 | 3,500 | SEC | ||
| Mar 13, 2008 | Mar 17, 2008 | Monogram Biosciences, Inc. | Director | AwardedStock Option (Rt to Buy) | 20,000 | 20,000 | SEC | ||
| Mar 29, 2007 | Apr 13, 2007 | Monogram Biosciences, Inc. | Director | AwardedStock Option (Right to Buy) | 20,000 | 20,000 | SEC | ||
| Apr 7, 2006 | Apr 11, 2006 | Monogram Biosciences, Inc. | Director | AwardedStock Option (Right to Buy) | 20,000 | 20,000 | SEC |